Gisele Zandman-Goddard

Gisele Zandman-Goddard

Auto-generated profile, based on publicly available information

Gisele Zandman-Goddard

Wolfson Medical Center

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2013 in BMC Medicine
Verified
Journal Article
Open access
PDF file
CRCristina Rosário
Cristina Rosário
GZGisele Zandman-Goddard
Gisele Zandman-Goddard
EMEsther Meyron-Holtz
Esther Meyron-Holtz
DDDavid P D’cRuz
David P D’cRuz
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
Background: Over the last few years, accumulating data have implicated a role for ferritin as a signaling molecule and direct mediator of the immune system. Hyperferritinemia is associated with a multitude of clinical conditions and with worse prognosis in critically ill patients. Discussion: There are four uncommon medical conditions characterized by high levels of ferritin, namely the macrophage activation syndrome (MAS), adult onset Still’s disease (AOSD), catastrophic antiphospholipid syndrome (cAPS) and septic shock, that share a similar clinical and laboratory features, and also respond to similar treatments, suggesting a common pathogenic mechanism. Ferritin is known to be a pro-inflammatory mediator inducing expression of pro-inflammatory molecules, yet it has opposing actions as a pro-inflammatory and as an immunosuppressant. We propose that the exceptionally high ferritin levels observed in these uncommon clinical conditions are not just the product of the inflammation but rather may contribute to the development of a cytokine storm. Summary: Here we review and compare four clinical conditions and the role of ferritin as an immunomodulator. We would like to propose including these four conditions under a common syndrome entity termed “Hyperferritinemic Syndrome”.

4 April 2013 in BMC Medicine
Verified
Journal Article
Open access
PDF file
ZRZiv Rosman
Ziv Rosman
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
GZGisele Zandman-Goddard
Gisele Zandman-Goddard
Biologic therapies for rheumatologic diseases, which are targeted at molecules involved in the mechanisms of the immune system, provide an alternative to the existing treatment methods of disease-modifying anti-rheumatic drugs and other immunosuppressive medications. However, the current drawbacks of biologic therapies, including the inconvenience of intravenous administration, the high costs of these drugs, and the adverse events associated with them, prevent their wide use as first-line medications. This review provides an update of the recent literature on the new biologic therapies available. The review concentrates on nine drugs: tocilizumab, rituximab, ofatumumab, belimumab, epratuzumab, abatacept, golimumab, certolizumab, and sifalimumab, which are used as therapies for rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, or vasculitis.

4 March 2015 in BMC Medicine
Verified
Journal Article
Open access
PDF file
SKShaye Kivity
Shaye Kivity
Nancy Agmon LevinNancy Agmon Levin
Nancy Agmon Levin
GZGisele Zandman-Goddard
Gisele Zandman-Goddard
JCJoab Chapman
Joab Chapman
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
Neuropsychiatric symptoms affect nearly half of the patients with systemic lupus erythematosus; however, the effect on disease severity, quality of life, and prognosis is tremendous. Symptoms of neuropsychiatric systemic lupus erythematosus may range from mild diffuse ones, to acute life threatening events. Although the underlying mechanisms are still largely unraveled, several pathogenic pathways are identified, such as antibody-mediated neurotoxicity, vasculopathy due to anti-phospholipid antibodies and other mechanisms, and cytokine-induced neurotoxicity. In the current review, we describe the old and the new regarding epidemiology, pathophysiology, diagnosis, and management of neuropsychiatric systemic lupus erythematosus. The possible link between neuropsychiatric symptoms and specific mechanisms may help to facilitate our understanding of the disease in the future, thus allowing for better treatment strategies.

7 November 2011 in Lupus
Verified
Journal Article
Closed access
PDF file
GZG Zandman-Goddard
G Zandman-Goddard
MSM Solomon
M Solomon
ZRZ Rosman
Z Rosman
EPE Peeva
E Peeva
YSY Shoenfeld
Y Shoenfeld
Clinical manifestations of lupus are encountered in a variety of disease entities, including isolated cutaneous lupus, undifferentiated connective tissue disease, mixed connective tissue disease, drug-induced lupus, overlap syndrome, and systemic lupus erythematosus (SLE). While each entity has been recognized as a specific disease with its own diverse clinical and serological pattern, one could argue that many findings are common. Could it be that all of these entities actually represent a spectrum of one disease? Could it be that rather than the genetic predisposition and hence controlled factors that govern this spectrum of diseases, that environmental factors associated with SLE could also play a role in the different entities of this spectrum? The traditional environmental triggers in SLE include sunlight and ultraviolet (UV) light, infections, smoking, and medications including biologics such as tumor necrosis factor alpha (TNF-a) blockers. In this review, we update and further substantiate these traditional factors in the various lupus-related syndromes. We will also discuss the association with vaccine exposure, industrial estrogens, and other factors.

10 April 2013 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
SKSaakshi Khattri
Saakshi Khattri
GZGisele Zandman-Goddard
Gisele Zandman-Goddard

1 January 2008
Verified
Journal Article
Closed access
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
GZGisele Zandman-Goddard
Gisele Zandman-Goddard
LSLjudmila Stojanovich
Ljudmila Stojanovich
MCMaurizio Cutolo
Maurizio Cutolo
HAHoward Amital
Howard Amital
YSYaniv Sherer
Yaniv Sherer